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Abstract: To attain effective and safe pharmacotherapy in neonates, caregivers have to consider both the clinical 
characteristics of the newborn and the pharmacokinetic estimates of a given compound during prescription and ad-
ministration. Overall, clearance in neonates is low when compared to other pediatric subpopulations. Despite this 
overall low clearance, there is already extensive between individual variability in clearance in early life. As a con-
sequence, neonates are in urgent need of tailored drug product development that considers the need for both low and flexible dosing to 
maintain dose accuracy.  
During the development of such formulations tailored for neonates, there is also a need for guidance on excipient exposure. The available 
knowledge on the safety or toxicity of excipients is limited and difficult to retrieve, but there are initiatives (e.g. Safety and Toxicity of 
Excipients for Pediatrics [STEP] database initiative) to improve the present situation. In addition, population focussed studies on aspects 
of clinical pharmacology of excipients in neonates should be conducted. The propylene glycol research project and the European Study 
for Neonatal Excipient Exposure (ESNEE) initiative illustrate its feasibility. Finally, until tailored formulations make it to the market, 
compounding practices for drug formulations in neonates should be evaluated to guarantee correct dosing, product stability, safety and to 
support pharmacists in their daily practice.  
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INTRODUCTION 
 Effective and safe drug administration in neonates should be 
based on the integration of knowledge related to the evolving 
physiological characteristics of the newborn to be treated with a 
given compound, and the pharmacokinetic and pharmacodynamics 
characteristics of this specific compound [1-4]. Children display 
maturation in the disposition of drugs, and this maturation is most 
pronounced in the first months of postnatal life. There are age-
dependent changes in body composition (e.g. water content) while 
almost all phase I (e.g. cytochrome P450 iso-enzymes) and phase II 
(e.g. glucuronidation, sulphation) metabolic processes mature with 
an iso-enzyme specific pattern. In addition, renal elimination clear-
ance also displays a maturational increase and almost exclusively 
depends on glomerular filtration [1-4].  
 The limited size (0.5-5 kg) does not exclude an extensive vari-
ability in clearance within this specific group of patients since there 
is already one log value in weight differences. Even more than the 
low median estimates of clearance, covariates of variability within 
this specific population are of clinical relevance. Besides weight, 
other covariates (e.g. co-medication, perinatal asphyxia, intrauterine 
growth restriction, postnatal age, postmenstrual age) further con-
tribute to the variability in clearance within the neonatal population 
[5,6].  
 When we aim to translate the combination of the overall low 
clearance with extensive variability within the neonatal age range, 
this results in the need for both low, adjustable and flexible dosing 
in early life to maintain dosing accuracy. As a consequence, formu-
lations for neonates need to consider these prerequisites [7]. Be-
cause of the specific characteristics of neonates, commonly 
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administered formulations are either liquids (e.g. drops, syrup) or 
vials for intravenous administration. The available data on the rele-
vance and the add-on value of tailored formulations in neonates will 
be discussed. This also includes the aim to validate the practice of 
extemporaneous formulation or compounding for neonates. Tai-
lored formulations hereby aim to result in more accurate, predict-
able and safe exposure to drugs for neonates [1,7]. 
 A specific issue that warrants focussed attention in neonatal 
formulation are the excipients used. As recently reviewed in this 
journal, pattern recognition of covariates should improve the feasi-
bility to perform clinical studies and to guide product development 
for neonates [4]. The same above mentioned maturational changes 
will also have impact on the pharmacokinetics and –dynamics of 
excipients (i.c. ‘excipient’-kinetics and –dynamics) commonly used 
during product development [8-10]. Consequently, there is an ur-
gent need to collect and summarize the already available knowledge 
on the clinical pharmacology of excipients in neonates: to make 
already available data accessible. The approach used in the devel-
opment of the Safety and Toxicity of Excipients for Paediatrics 
(STEP) database will be discussed as an illustration of this ap-
proach [11]. Such databases should provide us with data on knowl-
edge gaps in need of focussed research initiatives: to generate data 
on the knowledge gaps. We will illustrate the feasibility of such 
research initiatives based on the Leuven propylene glycol research 
project and on the European Study for Neonatal Excipient Exposure 
(ESNEE) initiative [12-16]. 
 The relevance of tailored formulations in neonates we be dis-
cussed first. This also includes the validation of compounding prac-
tices. This will be followed by topics related to the population spe-
cific clinical pharmacology of excipients in neonates. We hereby 
aim to describe a roadmap to further improve the pharmaceutical 
practice for (pre)term neonates.  
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NEONATAL DRUG FORMULATIONS 
The Relevance of Tailored Formulations 
 Neonates should receive formulations of which the pharmaceu-
tical design is tailored for use in this specific population [5,9,17, 
18]. Volume overload should be avoided, while too low volumes or 
too concentrated formulations may result in either dose inaccuracy 
due to either inaccurate volumes or inaccurate serial dilutions in 
order to achieve the required dose [17,18]. There are observations 
on the impact of serial dilutions of inotropics to illustrate the extent 
of dosing inaccuracy [19]. In contrast, a recent illustration of such 
an tailored formulation approach for neonates is the development of 
a caffeine containing vial (Peyona®) for treatment of apnoea of 
prematurity (20 mg/ml of caffeine citrate, equal to 10 mg/ml of 
caffeine base).  
 Nunn et al. recently quantified the practice of medicines ma-
nipulation to provide accurate doses for children, including neo-
nates in one regional children’s hospital [20]. Based on 5 375 drug 
administration events recorded in neonatal and pediatric patients, 
about 10 % were judged to require manipulation or needed a small 
dosing volume (< 0.2 ml). Measure doses below 0.1 ml accounted 
for 25 % of the manipulations, and this was most common in the 
neonatal intensive care unit (60 %) [20].  
 Oral administration can be achieved by several types of dosage 
forms. However, because of the need for dosing flexibility and the 
inability to swallow solid unit dosage forms, oral liquid formula-
tions (e.g. syrup, liquid drops) are preferred in neonates and young 
infants [3,21,22]. For the enteral route, specific issues that need to 
be considered in neonates are the impact of tube feeding or simulta-
neous administration with milk on the bioavailability of the phar-
maceutical product. For oral drugs commonly administered by a 
feeding tube (e.g. in preterm neonates), issues related to particle 
size, viscosity, dosing volume and compatibility with the tube mate-
rial should be considered [3,21,22]. 
 Most vials for intravenous administration contain relatively 
high concentrations of the active compound, inadequate for small 
neonates or infants. Tailored vials for intravenous administration, 
resulting in appropriate, flexible and correct dosage of drugs in 
neonates are needed. Besides the fact that 10 fold errors are more 
common when ‘highly’ concentrated formulations are used, this 
also relates to dilution related errors resulting in dosing inaccuracy 
[7,18,23,24].  
 We have illustrated this for amikacin (pediatric vial 50 mg/ml 
compared to the ‘adult vial’ 250 mg/ml), hereby applying a popula-
tion PK approach (NONMEM) to estimate clearance (CL) and vol-
ume of distribution (V) changes as markers for dose accuracy and 
variability from time-concentration profiles [25]. Differences in 
parameter estimates and their variability before and after introduc-
tion of the 50 mg/ml pediatric vial hereby reflect differences in dose 
accuracy. The final model demonstrated an apparent 8 % reduction 
in the estimate of V and a 29 % reduction of its variability after 
introduction of the pediatric vial. Clearance was the same in neo-
nates given adult or pediatric vials, but clearance variability was 
reduced by 53 %. Based on these observations, we concluded that 
the introduction of a pediatric vial was associated with a reduction 
in V and CL variability, reflecting improved dosing precision 
[23,25].  
The Practice of Compounding: Towards a Knowledge Driven 
Approach 
 At present, it is unlikely that commercially manufactured, 
ready-to-administer neonatal preparations are available for all com-
pounds prescribed. Marketed formulations do not always meet the 
specific requirement of all patient groups, commonly applicable for 
neonates (formulation, dose). As a consequence, it is reasonable to 
assume that compounding practices will remain common practice in 
near future [22,26,27].  
 The first intent of the manufacturer should be to provide an age 
appropriate formulation. An alternative could be that the manufac-
turer provides evidence on an appropriate compounding of a given 
formulation. A recent illustration of such an approach is the com-
pounding of an oral solution of valganciclovir [28]. Unfortunately, 
non-authorised (i.e. information not included in the Summary of 
product characteristics [SmPC]) compounding or manipulation is 
still very common, although the quality of compounding and ex-
cipient ingredients may vary considerably. This non-authorised 
approach may facilitate the use of a given drug in neonates but is 
unlicensed, and obviously carries risks of patient safety related to 
the quality of the formulation, the bioavailability of the compound 
and the excipients used for compounding [21,29]. A recent illustra-
tion of the need to validate such compounding practices is the 
evaluation of a paediatric oral formulation with a low proportion of 
hydrochlorothiazide, also suited for use in neonates. Santovena et 
al. hereby illustrated that only one of 5 suspensions of hydro-
chlorothiazide (2 mg/ml), guaranteed the correct dose administering 
and stability after 3 weeks of storage in predefined conditions [30].  
EXCIPIENTS IN NEONATAL DRUG FORMULATIONS 
Commonly Co-Administered, Rarely Considered 
 In addition to the parent compounds, drug formulations also 
contain excipients, needed as co-solvents, surfactants (general term 
for compounds that improve absorption, unrelated to the lung ‘sur-
factant’ administered for hyaline membrane disease), preservatives, 
colorants or sweeteners [31-33]. Examples of excipients are lactose, 
aspartame, ethanol, propylene glycol, benzyl alcohol, sorbitol, xyli-
tol, mannitol and poly-ethylene glycol. Such a definition suggest 
that excipients are only ‘innocent bystanders’ of the active com-
pound(s) in a specific formulation.  
 More recently, a more dynamic definition has been applied by 
the United States’ National Formulary [34]. This institution hereby 
refers to an excipient as ‘everything in the formulation in addition 
to the active compound(s)’. It refers to any substance that is used as 
vehicle or additive for administering drugs in the suitable consis-
tency or formulation. These excipients are added e.g. to ensure 
stability over a given shelf life, to improve palatability or to facili-
tate solubility or to bulk up formulations that otherwise contain 
highly potent active ingredients and are referred to as preservatives, 
sweeteners, fillers and solvents, coating materials or colouring 
agents [34].  
 In addition, excipients can further modulate the effects of a 
therapeutic compound. Examples of such more ‘interactive’ appli-
cations are e.g. liposomal amphotericin to avoid renal tubular toxic-
ity related to unbound amphotericin filtered by the renal glomerulus 
and subsequent resorption at the renal tubular cell [35]. Similarly, 
experimental data suggest that erythropoietin administration may 
serve as additional neuroprotective agent in neonates following 
peripartal asphyxia but that the positive effects in part depend on 
the permeability of the effect compartment (i.c. central nervous 
system) for erythropoietin [36]. In animal experimental setting, it 
has recently been described that transfer through the blood brain 
barrier of a nano-formulation (human recombinant EPO, PLGA-
EPO nanoparticles) results in a 10 fold higher bio-availability in the 
effect compartment [36]. As final illustration, the efficacy of inacti-
vated influenza vaccines is known to be poor in early life, but the 
use of an oil-in-water emulsion adjuvant results in a effective pro-
tection, defined by a reduction in influenza attack rates [37].  
 Although nearly all medicines are formulated with excipients 
that have been used for many years and are generally regarded as 
safe, usually referred to as ‘GRAS’ status, there are still disease 
specific issues (e.g. aspartame in patients with phenylketonuria, 
lactose in patients with lactase deficiency), and also issues related 
to specific populations like (pre)term neonates with their specific 
pharmacokinetics and –dynamics that needs further consideration 
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[32,34]. Historical observations, but also more recent case series 
repeatedly confronted clinicians with unanticipated, but sometimes 
predictable side-effects of neonatal drug formulations merely be-
cause of the excipients co-administrated. Benzyl alcohol [38-42] 
and propylene glycol [12,13,42,43] will be used as illustrations of 
the relevance to consider pharmacokinetics, while ethanol can be 
used as an example to consider pharmacodynamics of excipients in 
neonates [44]. Table 1 provides some additional information on the 
link between clinical syndromes and excipient exposure in neo-
nates.  
Table 1. Illustrations of specific clinical syndromes in neonates 
and associated excipient exposure. 
Specific clinical syndrome excipient exposure 
Raised hyperbilirubinaemia parabens (methyl- and propyl parahy-
droxybenzoate) sodium benzoate 
Seizures propylene glycol, accumulation benzyl 
alcohol, accumulation 
Central nervous system 
depression 




propylene glycol, accumulation polysor-
bate 80 
Metabolic acidosis propylene glycol, accumulation polysor-
bate 80 benzyl alcohol 
 
 Fatal benzyl alcohol-related poisoning has been described in a 
case series of 10 low birth weight infants. Benzyl alcohol was co-
administered in these neonates since included in an intravenous 
formulation as a bacteriostatic agent [38-41]. After administration 
of at least 130 mg/kg of benzyl alcohol, these neonates developed 
metabolic acidosis and had an elevated Anion Gap from the second 
day of exposure onwards. These neonates subsequent developed 
progressive bradycardia, gasping and seizures [38-41]. Based on 
these observations, evidence was collected that this clinical syn-
drome in neonates is related to maturational deficiency of benzyl 
alcohol degradation (benzyl alcohol to benzoic acid to hippuric 
acid) capacity, resulting in accumulation and subsequent toxic ef-
fects [38-41].  
 Propylene glycol toxicity in preterm neonates has also been 
documented since preterm neonates developed biochemical abnor-
malities, including hyperosmolarity, lactic acidosis, elevated 
creatinine and bilirubin following exposure of up to 3 000 mg/day 
of propylene glycol for at least 5 days. These biochemical abnor-
malities were followed by clinical symptoms, including seizures 
and bradycardic episodes [45,46]. Only recently, it was described 
that there is a much lower clearance capacity in neonates, in part 
depending on birth weight and on postnatal age [43].  
 Although these case series go back to the 1980s, the propylene 
glycol example also illustrates that this issue still remains of con-
temporary relevance. In March 2011, The US Food and Drug Ad-
ministration notified healthcare professionals of serious health 
problems that had been reported in premature babies receiving Ka-
letra® (lopinavir/ritonavir) oral solution [47]. This is an antiviral 
medication used in combination with other antiretroviral drugs for 
the treatment of HIV-1 infection. However, this Kaletra oral solu-
tion contains both relevant amounts of ethanol (42.4 % v/v) and 
propylene glycol (15.3 % w/v). Based on the reported side effects, 
the FDA claimed that premature babies may be at increased risk for 
health problems because they have a decreased ability to eliminate 
propylene glycol. This limited elimination capacity potentially re-
sults in adverse events such as serious cardiac, renal, metabolic and 
respiratory problems. Because the consequences of using Kaletra 
oral solution in neonates immediately after birth can be severe or 
possibly fatal, the label has undergone revision to include a new 
warning. The use of Kaletra oral solution should be avoided in 
premature babies until 14 days after their due date, or in full-term 
babies younger than 14 days of postnatal age unless a healthcare 
professional believes that the benefit of using Kaletra oral solution 
to treat HIV infection immediately after birth outweighs the poten-
tial risks. In such cases, FDA strongly recommends monitoring for 
increases in serum osmolality, serum creatinine, and other signs of 
toxicity [47]. 
 In addition to maturational pharmacokinetics, maturational 
pharmacodynamics should also be considered. Ethanol is known to 
be a neurotoxic compound, with age-specific impact on the fetal or 
neonatal brain (i.c. apoptosis and impaired synaptogenesis) with 
e.g. fetal alcohol syndrome [44]. Despite this, ethanol is still com-
monly used as an excipient for oral liquid formulations in (pre)term 
neonates.  
Lessons Learned from Recent Observations on Excipients 
 To raise awareness, we would like to stress that the above de-
scribed excipients are compounds to which neonates are quite regu-
larly exposed to in our neonatal intensive care units. Recent obser-
vations on the extent of the exposure have been reported from the 
United Kingdom [48], the United States [42], the Netherlands [49], 
Belgium [12,13,43] and most recently, from Estonia [14,15]. The 
key observations reported on the different epidemiological survey 
are also summarized in Table 2.  
 
Table 2. Lessons learned on contemporary excipient exposure 
in neonates. 
exposure is common: different cohorts in different countries all provide 
evidence for consistent, established exposure to excipients, including ex-
cipients linked to relevant clinical syndromes in neonates.  
the range in exposure is extensive: despite the established exposure, there is 
relevant variability in the amount of excipients exposed to. Bronchopulmon-
ary dysplasia and critical illness were two relevant covariates that were 
associated with higher excipient exposure.  
exposure is difficult to quantify: excipients are commonly but not routinely 
mentioned on formulations. Even if mentioned qualitatively, amounts are 
only rarely mentioned on the SmPC. This has been observed in different 
settings.  
exposure can be avoided: Interestingly, there are different formulations for 
different active compounds. There is a gentamicin formulation containing 
both parabens and sodium metabisulphite, while another formulation is free 
of these excipients. Similar, phenobarbital formulations contain different 
amounts of propylene glycol (5 fold difference when expressed in mg pro-
pylene glycol/mg phenobarbital) and there is even an formulation free of 
propylene glycol. This means that to a certain extent, excipient exposure can 
even be avoided.  
 
 Whittaker et al. [48] quantified the extent of exposure to poten-
tial toxic excipients following administration of oral formulations in 
preterm neonates. These research groups hereby documented that 
53 % of the eligible target group were exposed to potential toxic 
excipients during their in-patient stay. These infants were exposed 
to over 20 excipients including ethanol and propylene glycol, 
chemicals associated with neurotoxicity. Infants with chronic lung 
disease were exposed to higher concentrations of these excipients. 
Infants were also exposed to high concentrations of sorbitol, with 
some infants being exposed to concentrations in excess of recom-
mended guidelines for maximum exposure in adults. Similar, the 
ethanol exposure was also commonly above 1 unit/week of adult 
equivalent intake. Finally, propylene glycol exposure, co-
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administered with a dexamethasone liquid formulation commonly 
resulted in a weekly exposure above the 150 mg/kg/week limit for 
adults [48]. Likewise, Shehab et al. quantified the exposure to ben-
zyl alcohol and propylene glycol in critically ill neonates or infants 
[42]. Based on 170 episodes of benzyl alcohol (n=88) and/or pro-
pylene glycol (n=82) exposure, a wide range in cumulative excipi-
ent dose was documented [4.5 (0.6-319) mg/kg/day for benzyl al-
cohol and 204.9 (17-9 473) mg/kg/day for propylene glycol respec-
tively][42].  
 Riet-Nales et al. reviewed the availability and age-
appropriateness of medicines for children in the Netherlands [49]. 
In an at random sample of 400 oral liquid preparations, authoriza-
tion for use in newborns was limited (37 %), and 52 % contained 
potential harmful excipients. For parenteral preparations, 7 % con-
tained potential harmful excipients. Interestingly, the same active 
compound but without such ‘potential harmful’ excipient was 
available in 22 % of the formulations [49]. 
 In Belgium, we recently reported on a focussed study on as-
pects of the clinical pharmacology of propylene glycol exposure 
following intravenous co-administration in neonates [12,13,43]. We 
hereby documented that a median exposure to 34 mg/kg/day of 
propylene glycol was tolerated well [13]. Interestingly, during the 
design of the study, we also had difficulties to retrieve the exact 
composition of the propylene glycol containing phenobarbital vial 
commonly used in our unit [12].  
 Recently (2012), a nationwide survey on the extent of excipient 
exposure to neonates has been reported from Estonia [14,15]. Based 
on 1961 prescriptions on 107 different formulations during a 6 
month time interval, exposure to 123 excipients in 348/490 neo-
nates was documented. Of these excipients, 47/123 (38 %) were 
classified as ‘toxic or potential toxic’ for neonates. Almost all ad-
mitted neonates (97 %) were exposed to at least one for these ‘toxic 
or potential toxic’ excipients [14,15]. Despite the fact that 19 for-
mulations were licensed for use in neonates, about half of them 
contained at least one potential harmful excipient.  
 Parabens and sodium metabisulphite were the most commonly 
administered ‘toxic or potential toxic’ excipients administered in 
this Estonian cohort but exposure to sodium benzoate, benzyl alco-
hol, propylene glycol, polysorbate 80 and ethanol was also ob-
served [14,15]. Interestingly, the exposure to parabens and sodium 
metabisulphite seems to relate to a specific gentamicin formulation 
available in Estonia. The authors hereby mention that the informa-
tion currently mentioned on the SmPC was not always complete, 
that the amount of excipients in a specific formulation was only 
mentioned in 2/19 SPC documents approved for use in (pre)term 
neonates. This confirms the Belgian observation on the difficulties 
to retrieve the exact amounts of propylene glycol in intravenous 
phenobarbital formulations administered to newborns [12]. Moreo-
ver, it turned out that there are also parabens/sodium metabisulphite 
free gentamicin formulations and even propylene glycol free phe-
nobarbital formulations available in some specific countries or re-
gions [14,15,50].  
Towards a Tailored, Knowledge Driven Approach of Excipients 
 The recent epidemiological findings confirm the established 
exposure to excipients, the difficulty to retrieve the exact amounts 
of exposure, and the unanticipated observations that both excipient 
containing and excipient free formulations for the same therapeutic 
compound are available. Recently initiated research activities to 
ameliorate the access to information on excipients in neonates 
(STEP database, i.e. Safety and Toxicity of Excipients for Paediat-
rics database) [11] or to generate new information (ESNEE research 
initiative, European Study for Neonatal Excipient Exposure) on the 
epidemiology and the tolerance of excipients are very useful ap-
proaches [16]. 
 Excipient safety data are publicly available in peer-reviewed 
scientific journals, government reports and databases, but there is 
limited information on data to guide neonatal drug development. 
Moreover, the available information is distributed over many 
sources. The European Paediatric Formulation Initiative (EuPFI) 
took – in collaboration with the Food and Drug Administration, 
European Medicines Agency and pharmaceutical industry - the 
initiative to collect and structure retrievable information on excipi-
ents in the ‘STEP’ database. The main aims of this STEP initiative 
are (1) to conduct a systematic review on the pharmacology, toxi-
cology and safety data of excipients considered to be used in paedi-
atric formulations, (2) to help determine the relationship between 
exposure and toxicity in the paediatric age group or in specific pae-
diatric subpopulations like neonates, and (3) to identify knowledge 
gaps and needed studies [11]. Such a database provides 
stakeholders a basis for screening and selecting excipients for use in 
paediatric product development.  
 The European Study for Neonatal Excipient Exposure (ESNEE 
research initiative) has been funded by the ERA-NET PRIOMED-
CHILD, a multinational European research initiative with specific 
focus on developmental clinical pharmacology [16]. This research 
initiative aims to build a platform for systematic assessment of 
excipients in neonates. The first step is about ‘setting the scene’: 
which excipients are in use and how much of each excipient is in-
cluded in medicines given to neonates. The above described data on 
excipient exposure in Estonian neonates related to this ESNEE 
initiative [16]. A second step of this ESNEE program is to deter-
mine what is known about the effects of excipients in neonates and 
juvenile animals. To do so, the research initiative aims to develop a 
series of systematic reviews about excipient toxicity in neonates.  
 The third step is to ‘generate information on missing links’: to 
quantify concentrations of key excipients in neonates using dry 
blood spots and plasma samples. The final step of the ESNEE pro-
gram is to integrate this work into a systematic assessment of safety 
for each excipient: ‘back to the clinical relevance’. A generic 
framework for the assessment of excipient safety in neonates will 
be developed [16]. Propylene glycol may hereby serve as a case 
study with reference to other excipients to at least illustrate its fea-
sibility. We recently published our experiences on the feasibility 
and the methodology applied to evaluate pharmacokinetics and –
dynamics of propylene glycol [12,13,43]. This approach included 
population pharmacokinetics, systematic collection of clinical ob-
servations and comparison of excipient exposed compared to non-
exposed neonates [12,13].  
GENERAL DISCUSSION 
 Children display maturation in drug disposition, but this is most 
prominent in the first months of postnatal life. Although the princi-
ples of drug disposition also apply in neonates, their specific char-
acteristics warrant focussed assessment. As a consequence, neo-
nates are in need of tailored drug development and clinical research 
should hereby focus on both new as well as already existing com-
pounds [27,51,52]. Good prescribing involves assurance that the 
drug administered is of sufficient pharmaceutical quality, that an 
appropriate formulation is used (excipient, dose accuracy), and that 
there is sufficient knowledge on the pharmacokinetics, -dynamics 
and safety of the compound administered [27,51,52].  
 We hereby aimed to stress that tailored, personalized clinical 
pharmacology for neonates also needs considerations related to 
neonatal formulations and additives. Similar to the increasing 
knowledge on clinical pharmacology of the active compounds ad-
ministered to neonates, we should aim to increase the knowledge 
and the validity of this knowledge on excipient exposure in neo-
nates [22,31]. We need to learn more on the appropriateness of 
established excipient use in neonatal drug formulations [9,10, 
27,48]. We hereby have to aware that authorised medicinal products 
with given excipients do not necessary reflect the gold standard, nor 
Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach Current Pharmaceutical Design, 2015, Vol. 21, No. 00    5 
does this validate the unrestricted use of the same excipient in an-
other formulation: established practice is not always equal to best 
practice [5,52]. 
 Further progress can be made in collaborative efforts between 
industry, caregivers, academia and regulatory agencies and should 
focus on product availability (tailored formulations), knowledge 
integration of currently available information and make such infor-
mation accessible (e.g. STEP database), validation of the assumed 
safety of currently used excipients (ESNEE study project), and the 
validation of procedures and practices on compounding. 
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